Form 4: Oncocyte CFO Andrea James Acquires 33,670 Shares in Private Placement
SEC Form 4
Andrea James, CFO of Oncocyte Corp, purchased 33,670 shares of common stock in a private placement on October 2, 2024.
Summary
- On October 2, 2024, Andrea James, the Chief Financial Officer of Oncocyte Corporation, acquired 33,670 shares of the company's common stock.
- The shares were purchased at a price of $2.97 per share.
- The acquisition was part of a private placement agreement between Oncocyte and signatory investors.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CFO's purchase indicates confidence, but it's a single transaction and doesn't provide a comprehensive view of the company's health.
Positives
- The CFO's investment in the company may signal confidence in Oncocyte's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company insider believes the company's stock is undervalued. However, it's important to consider the context of the purchase, such as the size of the purchase relative to the insider's holdings and the company's overall financial situation.
Stakeholder Impact
- The purchase could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 10/02/2024 | Date of the transaction: Andrea James purchased 33,670 shares of Oncocyte Corp common stock. |
| 10/04/2024 | Date of signature on the SEC Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.